Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Includes 30 eligible patients who take 12 mg of gm daily every 8 hours for 60 days prior to ovulatory surgery. Pharmaceutical company: Algalif. Intervention 2: Cont
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Age range 18 to 35 years Body mass index (BMI) range of more than 20 and less than 30 PCOS according to the Rotterdam criteria
Exclusion criteria
Exclusion criteria: Pregnancy Having other endocrine disorders such as adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, thyroid dysfunction Having any infectious disease Having diabetes or impaired glucose tolerance Infertility with male factors Use of antioxidant supplements, ovulation-inducing drugs, or drugs affecting the hormonal profile within 6 months prior to the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ART Cycle Outcomes. Timepoint: After completing the intervention. Method of measurement: Pregnancy test and microscope. | — |
Secondary
| Measure | Time frame |
|---|---|
| MDA(Malone dialdehyde). Timepoint: After the intervention begins. Method of measurement: ELISA.;TAC(Total Antioxidant Capability). Timepoint: After the intervention begins. Method of measurement: ELISA.;Yes-associated protein. Timepoint: After the intervention id completed. Method of measurement: Western blot.;Phosphorylated Yes-associated protein (p-Yap). Timepoint: After the intervention id completed. Method of measurement: Western blot.;Cellular Communication Network Factor 2 (CCN2) Protein. Timepoint: After the intervention id completed. Method of measurement: Western blot.;Yes-associated protein Gene. Timepoint: After the intervention id completed. Method of measurement: Real Time PCR.;Larg tumor suppressor kinase1(LATS1). Timepoint: After the intervention id completed. Method of measurement: Real Time PCR.;TEA domain family member1 Gene(TEAD1). Timepoint: After the intervention id completed. Method of measurement: Real Time PCR.;Protein BCL-2-Associated X protein(BAX). Timepoint: After the intervention id completed. Method of measurement: Real Time PCR.;B- cell lymphoma2 protein(BCL2). Timepoint: After the intervention id completed. Method of measurement: Real Time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahareh Babaei Hoolari
Tehran University of Medical Sciences
Outcome results
None listed